Tumour necrosis factor alpha inhibitors for the treatment of adult rheumatoid arthritis
There are much cheaper drugs for controlling TNF production such as thalidomide and oxpentifylline (pentoxifylline). 2 Thalidomide may be in the 'too-hard basket', but oxpentifylline has been used for more than 30 years to treat poor circulation. 3 Oxpentifylline is a proven alternative to steroids for controlling granulomatous inflammation in Hansen's disease. 4, 5 So its safety is not an issue. Its short half-life 3 permits rapid suspension of use should compromising situations such as infections arise. For optimal efficacy in treating chronic inflammation oxpentifylline may have to be used synergistically. 6 
Dispensing practices and labelling of drugs
Editor, -As a consumer of various prescription drugs I am concerned at the dispensing practices of some pharmacists with regard to exterior packaging of jars containing drugs.
For example, one of the drugs I regularly take is methotrexate which is packed into a small plastic jar, which is then packed inside a box. The extra packaging (that is, the box) is usually discarded and the jar containing the tablets is kept in the cabinet. What concerns me is that the In such cases it would be reasonable to expect the pharmacist to provide verbal reinforcement of the key messages as well as perhaps an explanation of why the dispensing label has not been placed on the primary container.
In some instances it may also be beneficial if the patient was able to communicate their preference to assist with safe and appropriate administration and quality use of medicines. 
Changes to the shelf-life of thyroxine
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While Thyroid Australia understands and appreciates the TGA's efforts to ensure the potency of thyroxine for the entirety of its shelf-life, we view the change to refrigeration as a retrograde step in the treatment of hypothyroidism in Australia.
We are concerned that this change could have a negative impact on compliance. In addition, it seems Australia is the only country where thyroxine tablets require refrigeration. In many countries the shelf-life unrefrigerated is much longer than 18 months. This leads Thyroid Australia to question the TGA's approach to remedying potency issues with thyroxine.
Addressing the matter by introducing refrigeration places the burden on patients.
Due to thyroxine, hypothyroidism is a readily treatable condition.
It enables affected individuals to lead very close to normal lives.
This change moves hypothyroidism from a condition that can be easily lived with, to a condition that impinges upon everyday life.
In particular, it places limits on travel and spontaneity. We hope that refrigeration is only an interim measure until a more viable long-term solution is found.
Gail Pascoe President, Thyroid Australia Melbourne
Dr Leonie Hunt, Assistant Secretary, Drug Safety & Evaluation Branch, Therapeutic Goods Administration, comments:
The Therapeutic Goods Administration has been working with the manufacturer and sponsors of thyroxine tablets to review the potency of the tablets throughout their shelf-life.
There have been a number of consumer complaints about apparent lack of potency of thyroxine tablets over time. It is apparent that these tablets do not maintain their full potency if stored at room temperature.
For this reason it has been considered necessary to change recommended storage conditions of the tablets so they are now recommended to be stored in the refrigerator. It is essential that there be no significant variability in the potency of tablets either within any one bottle of tablets or between successive bottles of tablets. Refrigerated storage will assist in this endeavour.
The shelf-life of a medicine in any country will depend on a number of factors including the manufacturing within that country, room temperature conditions and factors related to the final formulation sold in the market place. What is important is that the shelf-life and storage conditions chosen for a market place result in the brands in that market place having reliable stability and potency over time.
Editorial note:
Sigma Pharmaceuticals, the manufacturer of thyroxine tablets, did not wish to add to the discussion. Although this has not been tested in an Australian court, it has been tested in US courts and found not to breach US legislation. 2 In addition to legal issues, however, clinical and ethical issues, including patient consent, also need to be considered in any decision to prescribe medicines off-label. The NSW TAG Discussion Paper highlights these issues and provides a systematic approach to addressing them. The paper may be 
Off-label prescribing
